• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.

作者信息

Tiacci Enrico, De Carolis Luca, Simonetti Edoardo, Merluzzi Mara, Bennati Antonio, Perriello Vincenzo Maria, Pucciarini Alessandra, Santi Alessia, Venanzi Alessandra, Pettirossi Valentina, Schiavoni Gianluca, Tasselli Luisa, Ascani Stefano, Volpetti Stefano, Falini Brunangelo

机构信息

Hematology, University and Hospital of Perugia, Perugia, Italy.

Anatomic Pathology, University of Perugia and Hospital of Terni, Perugia, Italy.

出版信息

Leukemia. 2021 Nov;35(11):3314-3318. doi: 10.1038/s41375-021-01210-8. Epub 2021 Mar 17.

DOI:10.1038/s41375-021-01210-8
PMID:33731847
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8550943/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04e9/8550943/12c328882179/41375_2021_1210_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04e9/8550943/12c328882179/41375_2021_1210_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/04e9/8550943/12c328882179/41375_2021_1210_Fig1_HTML.jpg

相似文献

1
Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial.BRAF抑制剂达拉非尼治疗复发或难治性毛细胞白血病的安全性和有效性：一项2期临床试验试点研究
Leukemia. 2021 Nov;35(11):3314-3318. doi: 10.1038/s41375-021-01210-8. Epub 2021 Mar 17.
2
Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib.难治性毛细胞白血病对BRAF抑制剂达拉非尼的快速且完全血液学缓解
Ann Hematol. 2014 Dec;93(12):2087-9. doi: 10.1007/s00277-014-2104-2. Epub 2014 May 27.
3
BRAF inhibitor therapy in HCL.毛细胞白血病中的BRAF抑制剂疗法。
Best Pract Res Clin Haematol. 2015 Dec;28(4):246-52. doi: 10.1016/j.beha.2015.10.001. Epub 2015 Oct 20.
4
Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.用BRAF抑制剂达拉非尼联合治疗毛细胞白血病和黑色素瘤。
J Natl Compr Canc Netw. 2015 Jan;13(1):9-13; quiz 13. doi: 10.6004/jnccn.2015.0004.
5
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.泊马度胺治疗复发/难治性毛细胞白血病。
Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.
6
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.辅助达布拉非尼联合曲美替尼对比安慰剂治疗 BRAF 突变型 III 期黑色素瘤患者（COMBI-AD）：一项随机、III 期临床试验的探索性生物标志物分析。
Lancet Oncol. 2020 Mar;21(3):358-372. doi: 10.1016/S1470-2045(20)30062-0. Epub 2020 Jan 30.
7
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.靶向复发性或难治性毛细胞白血病中的突变型BRAF
N Engl J Med. 2015 Oct 29;373(18):1733-47. doi: 10.1056/NEJMoa1506583. Epub 2015 Sep 9.
8
Sustained response to salvage therapy for dabrafenib-resistant metastatic Langerhans cell sarcoma.对达拉非尼耐药的转移性朗格汉斯细胞肉瘤挽救治疗的持续反应
Ann Oncol. 2016 Dec;27(12):2305-2307. doi: 10.1093/annonc/mdw299. Epub 2016 Aug 8.
9
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.在既往多次治疗的复发/难治性毛细胞白血病（HCL）患者中，给予莫昔妥珠单抗帕司努他（moxetumomab pasudotox）治疗：关键性试验的长期随访结果。
J Hematol Oncol. 2021 Feb 24;14(1):35. doi: 10.1186/s13045-020-01004-y.
10
Therapy with mosunetuzumab, a bispecific antibody for relapsed/refractory hairy cell leukemia.用莫苏奈妥珠单抗治疗复发/难治性毛细胞白血病，莫苏奈妥珠单抗是一种双特异性抗体。
Leuk Lymphoma. 2024 May;65(5):684-687. doi: 10.1080/10428194.2024.2304026. Epub 2024 Jan 22.

引用本文的文献

1
CD103-Negative Hairy Cell Leukemia: A Case Report From University Teaching Hospital, Zambia.CD103阴性毛细胞白血病：赞比亚大学教学医院的一例病例报告
Case Rep Med. 2025 Jul 11;2025:7084757. doi: 10.1155/carm/7084757. eCollection 2025.
2
COVID-19 vaccination in patients with classic and variant hairy cell leukemia.经典型和变异型毛细胞白血病患者的新冠病毒疫苗接种
Blood Neoplasia. 2024 Aug 28;1(4):100035. doi: 10.1016/j.bneo.2024.100035. eCollection 2024 Dec.
3
Gender Disparity in Enrollment in Clinical Trials for Hairy Cell Leukemia Treatments in the Last 40 Years.
过去40年毛细胞白血病治疗临床试验入组中的性别差异
EJHaem. 2025 May 22;6(3):e70065. doi: 10.1002/jha2.70065. eCollection 2025 Jun.
4
B Cell Activating Factor Induces Drug Resistance in Hairy Cell Leukemia Variant.B细胞活化因子诱导变异型毛细胞白血病的耐药性。
Biomedicines. 2025 Apr 7;13(4):890. doi: 10.3390/biomedicines13040890.
5
Pure Biclonal Hairy Cell Leukemia-Apt Diagnosis with Multicolor Flow Cytometry.纯双克隆毛细胞白血病——多色流式细胞术的精准诊断
Int J Hematol Oncol Stem Cell Res. 2024 Oct 1;18(4):400-402. doi: 10.18502/ijhoscr.v18i4.16764.
6
Recommendations for the Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group.毛细胞白血病和毛细胞白血病样疾病患者的管理建议：由法语专家和法国创新白血病组织（FILO）小组完成的一项工作
Cancers (Basel). 2024 Jun 10;16(12):2185. doi: 10.3390/cancers16122185.
7
Skin Hypopigmentation in Hematology Disorders.血液系统疾病中的皮肤色素减退
Hematol Rep. 2024 Jun 4;16(2):354-366. doi: 10.3390/hematolrep16020036.
8
BRAF - a tumour-agnostic drug target with lineage-specific dependencies.BRAF - 一种无肿瘤靶向药物靶点，具有谱系特异性依赖性。
Nat Rev Clin Oncol. 2024 Mar;21(3):224-247. doi: 10.1038/s41571-023-00852-0. Epub 2024 Jan 26.
9
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF-mutated melanoma.BRAF 突变型癌症中 vemurafenib 的长期疗效：ACSE 篮子研究——除 BRAF 突变型黑色素瘤以外的晚期癌症。
ESMO Open. 2023 Dec;8(6):102038. doi: 10.1016/j.esmoop.2023.102038. Epub 2023 Nov 1.
10
Targeting RAS-RAF-MEK-ERK signaling pathway in human cancer: Current status in clinical trials.靶向人类癌症中的RAS-RAF-MEK-ERK信号通路：临床试验现状
Genes Dis. 2022 May 20;10(1):76-88. doi: 10.1016/j.gendis.2022.05.006. eCollection 2023 Jan.